Get our weekly newsletter that 259K+ startup teams read
Omri Amirav-Drory, Ph.D. 24
Featured
The Next Industrial Revolution: Computational Biology & Bioplatforms
Post Image
Featured
NFX Bio: Investing in Scientist-Founders from the Very Beginning with Omri Amirav-Drory
Post Image
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
Post Image
Featured
Why C2i is the World’s First Platform for Cancer Intelligence
Post Image
A Scientific Approach To Your Company (And Your Life)
Post Image
A Scientific Approach to VC
Post Image
The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)
Post Image
Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery
Post Image
The Future of Longevity: Keeping Healthy People Healthy
Post Image
The 3 Waves of AI in Bio
Post Image
Maximizing TechBio Deal Potential: Platform vs. Asset Deals
Post Image
Deal or Die: Your 3-Part Guide to Business Development in TechBio
Post Image
Tech Founders, Don’t Be Afraid of Bio
Post Image
What Doesn’t Kill You, Mutates And Tries Again
Post Image
From Sick Care to Health Care: Why We Need Longevity Startups
Post Image
How to Prove Your TechBio Platform at Seed Stage
Post Image
Why NFX Invested in Centivax: The TechBio Platform Developing Universal Vaccines
Post Image
Academia or Startup? A Decision Matrix for Future Scientist-Founders
Post Image
The Golden Ratio: Navigating East Coast v. West Coast in TechBio Investing
Post Image
From Biotech to TechBio
Post Image
Why NFX Invested in Pangea Biomed, the Startup Matching Cancer Patients with the Right Therapies
Post Image
Why NFX Invested in Pepper Bio: The ‘Waze for Drug Discovery’ Will Treat the Untreatable
Post Image
Launching NFX Bio and The Rise of the Scientist Founder
Post Image
Difference Between BioTech & TechBio
Post Image

Try ChatNFX